Immunex Corporation

Amgen Inc.

Other

The State University of New York

Wyeth

Immuner Corp.

Max-Planck-Institute for Biochemistry

Raymond J Paxton

Kenneth H Grabstein

Dean K Pettit

Stewart D Lyman

Kirk P Van Ness

Jeremy Ian Levin

James Ming Chen

Michael Wittekind

Roy A Black

Wolfram Bode

Jill Kramer

James P Malone

Sarah L Gaffen

Fang Shen

Klaus Maskos

Walter Hanel

Carlos Fernandez-Catalan

Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided. Pharmaceutical compositions, B and T cell activation agents, assays and methods of use are also described.

Nucleic acids encoding modified human thymic stromal lymphopoietin

Modified human thymic stromal lymphopoietin

The invention provides isolated Pre-Ligand Assembly Domain (PLAD) polypeptides comprising an amino acid sequence of a domain (e.g., a Fibronectin Ill-like domain) of an IL-17 Receptor (IL-17R) family member, wherein the PLAD polypeptide inhibits multimerization of a receptor complex comprising an IL-17R family member. Also provided are isolated PLAD-binding polypeptides, e.g., antibodies and avimers, which specifically bind to a PLAD polypeptide described herein. Related chimeric proteins, conjugates, nucleic acids, vectors, and host cells are provided herein. Further provided are methods of treating an inflammatory or autoimmune disease, methods of inhibiting IL-17-mediated signal transduction, methods of inhibiting IL-17 ligand binding, methods of inhibiting multimerization of IL-17R complexes, and methods of inhibiting the production of at least one cytokine, chemokine, matrix metalloproteinase, or other molecule associated with IL-17 signal transduction are provided.

Pre-ligand assembly domain of the IL-17 receptor

Nucleic acid encoding modified human thymic stromal lymphopoietin

Antagonists of mammalian interleukin-15 ('IL-15') are disclosed and include muteins of IL-15 and modified IL-15 molecules that are each capable of binding to the IL-15R&#x3b1;-subunit and that are incapable of transducing a signal through either the &#x3b2;- or &#x3b3;-subunits of the IL-15 receptor complex. Also included are monoclonal antibodies against IL-15 that prevent IL-15 from effecting signal transduction through either the &#x3b2;- or &#x3b3;-subunits of the IL-15 receptor complex. Methods of treating various disease states are disclosed, including treating allograft rejection and graft-versus-host disease.

Antagonists of interleukin-15

Antagonists of mammalian interleukin-15 ('IL-15') are disclosed and include muteins of IL-15 and modified IL-15 molecules that are each capable of binding to the IL-15R&#x3b1;-subunit and that are incapable of transducing a signal through either the &#x3b2;- or &#x3b3;-subunits of the IL-15 receptor complex. Also included are monoclonal antibodies against IL-15 that prevent IL-15 from effecting signal transduction through either the &#x3b2;- or &#x3b3;-subunits of the IL-15 receptor complex. Methods of treating various disease states are disclosed, including treating allograft rejection and graft-versus-host disease,

A tumor necrosis factor-&#x3b1; converting enzyme (TACE) is produced, purified, and crystallized. The three-dimensional coordinates of the crystal are obtained by X-ray diffraction. The coordinates can be recorded on a computer readable medium, or are part of a video memory, where they can be used as part of a system for studying for studying TACE. The coordinates are also used in designing, screening, and developing compounds that associate with TACE.

Crystalline TNF-&#x3b1;-converting enzyme and uses thereof

Antagonists of mammalian interleukin-15 (&ldquo;IL-15&rdquo;) are disclosed and include muteins of IL-15 and modified IL-15 molecules that are each capable of binding to the IL-15R&agr;-subunit and that are incapable of transducing a signal through either the &bgr;- or &ggr;-subunits of the IL-15 receptor complex. Also included are monoclonal antibodies against IL-15 that prevent IL-15 from effecting signal transduction through either the B- or &ggr;subunits of the IL-15 receptor complex. Methods of treating various disease states are disclosed. including treating allograft rejection and graft-versus-host disease.

Antagonists of mammalian interleukin-15 (&ldquo;IL-l5&rdquo;) are disclosed and include muteins of IL-15 and modified IL-15 molecules that are each capable of binding to the IL-15R&agr;-subunit and that are incapable of transducing a signal through either the &bgr;- or &ggr;-subunits of the IL-15 receptor complex. Also included are monoclonal antibodies against IL-15 that prevent IL-15 from effecting signal transduction through either the &bgr;- or &ggr;-subunits of the IL-15 receptor complex. Methods of treating various disease states are disclosed, including treating allograft rejection and graft-versus-host disease.

Antagonists of mammalian interleukin-15 ('IL-15') are disclosed and include muteins of IL-15 and modified IL-15 molecules that are each capable of binding to the IL-15R.alpha.-subunit and that are incapable of transducing a signal through either the .beta.- or .gamma.-subunits of the IL-15 receptor complex. Also included are monoclonal antibodies against IL-15 that prevent IL-15 from effecting signal transduction through either the .beta.- or .gamma.-subunits of the IL-15 receptor complex. Methods of treating various disease states are disclosed including treating allograft rejection and graft-versus-host disease.

Antagonists of mammalian interleukin-15 ('IL-15') are disclosed and include muteins of IL-15 and modified IL-15 molecules that are each capable of binding to the IL-15R.alpha.-subunit and that are incapable of transducing a signal through either the .beta.- or .gamma.-subunits of the IL-15 receptor complex. Also included are monoclonal antibodies against IL-15 that prevent IL-15 from effecting signal transduction through either the .beta.- or .gamma.-subunits of the IL-15 receptor complex. Methods of treating various disease states are disclosed, including treating allograft rejection and graft-versus-host disease.

Growing community of inventors

Bellevue, WA, United States of America

Raymond J Paxton